A

ACADIA Pharmaceuticals
D

ACAD

15.330
USD
-0.79
(-4.87%)
مغلق
حجم التداول
67,842
الربح لكل سهم
0
العائد الربحي
-
P/E
11
حجم السوق
2,563,539,506
أصول ذات صلة
ABBV
ABBV
-13.045
(-6.47%)
188.520 USD
ALNY
ALNY
-21.680
(-8.26%)
240.730 USD
AMGN
AMGN
-15.77
(-5.08%)
296.45 USD
BIIB
BIIB
-6.460
(-4.94%)
124.230 USD
BMRN
BMRN
-7.190
(-10.65%)
60.300 USD
INCY
INCY
-1.890
(-3.02%)
60.610 USD
NBIX
NBIX
-7.980
(-7.75%)
94.930 USD
S
SAGE
-0.47500
(-6.44%)
6.90000 USD
S
SRPT
-3.990
(-6.80%)
54.680 USD
X
XNCR
-0.36000
(-4.04%)
8.54000 USD
المزيد
الأخبار المقالات

العنوان: ACADIA Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.